Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
TOKYO–(BUSINESS WIRE)– Alivexis, Inc. (headquartered in Tokyo, Japan, “Alivexis”) and Melodia Therapeutics AG (headquartered in Basel, Switzerland, “Melodia”), a company established by Forty51 Ventures, announced...